Drug profile · INN
caspofungin acetate
CANCIDAS
caspofungin acetate (CANCIDAS) is a 1,3-beta-glucan synthase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — caspofungin acetate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
caspofungin acetate (CANCIDAS) is a 1,3-beta-glucan synthase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
1,3-beta-glucan synthase inhibitor
Primary target: 1,3-beta-glucan synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is caspofungin acetate?
caspofungin acetate (CANCIDAS) is a 1,3-beta-glucan synthase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for caspofungin acetate?
CANCIDAS is a marketed brand name for caspofungin acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of caspofungin acetate?
caspofungin acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.